Trasylol (generic name: aprotinin), manufactured by Bayer A.G., was prescribed to patients undergoing heart surgery to control bleeding during and after the procedure. Trasylol was approved for use by the FDA in 1993 and had been widely prescribed until it was pulled from the market in 2007 after the FDA suspended its use. A CBS 60 Minutes report in 2008 revealed that Bayer knew of and had withheld a study showing the dangers of Trasylol in 2006. This study concludes that the risk of death is 64% higher with Trasylol compared to alternative anti-bleeding medications. This and other studies have proven Trasylol to double a patient's risk of serious side effects, such as heart failure, heart attack, stroke, and kidney failure, more than doubling the patient's risk of death.